0.01 | 2.20%
| Price and Volume | |
|---|---|
| Recent Price | 0.58 |
| 52 Week High | 2.27 |
| 52 Week Low | 0.39 |
| Avg. Daily Vol. (Mil) | 0.90 |
| Beta (3 year) | 2.04 |
| Share Related Items | |
| Mkt Cap (Mil) | 56.85 |
| Shares Out (Mil) | 98.87 |
| Float (Mil) | 71.90 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.40 |
| Current Ratio | 1.70 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 3.58 |
| Price/Book | 4.41 |
| Price/Cash Flow | -1.40 |
| Per Share Data | |
| Earnings | -0.55 |
| Sales | 0.16 |
| Book Value | 0.13 |
| Cash Flow | -0.41 |
| Business Summary | |
|---|---|
| Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company that manufactures and develops monoclonal antibodies for the treatment of cancer and serious viral infections. | |
| General Information | |
| 14282 Franklin Avenue
Suite 100 Tustin, CA 92780 |
|
| www.peregrineinc.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 154 | |
| CEO: Mr. Steven W. King | |
| Short Interest | |
| Current Month (Mil) | 4.77 |
| Previous Month (Mil) | 4.74 |
| Short Interest Ratio (Days) | 8.90 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -140.10 |
| Return on Investments | -319.00 |
| Profitability | |
| Gross Margin | 38.90 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,580.69 | 1,332.42 | 2,870.99 | 17.31 |
Oil *
106.79
|
|
UP
125.86 |
UP
14.60 |
UP
33.46 |
DOWN
0.14 |
10 Yr
1.73%
SPDR Gold
151.02
|
|
+1.01%
|
+1.11%
|
+1.18%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet